GSK plc and 35Pharma Inc.: what the $950m HS235 deal changes in pulmonary hypertension therapy
GSK is acquiring 35Pharma for $950 million to strengthen its pulmonary hypertension pipeline. Find out what HS235 changes and what risks remain.
Pharma & Biotech